The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone

Roger S McIntyre1,2

1Department of Psychiatry, University of Toronto. 2Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada

Abstract: Although many branded and generic antidepressants are approved for the treatment of major depressive disorder (MDD) in Canada, efficacy and tolerability differ among patients, and new treatment options are needed. Symptom types (eg, fatigue, energy/motivation, cognition, and functioning), medication type, treatment duration, and the need for maintenance therapy are factors that may influence treatment effectiveness. Three antidepressants, vortioxetine, levomilnacipran extended-release (ER), and vilazodone have recently become available in Canada. The aim of this review is to contextualize differences in their mechanistic and clinical profiles, thereby providing practitioners with knowledge to support treatment decisions. In trials versus placebo, each drug improved depressive symptoms in adult patients with MDD. The antidepressant effect of vortioxetine may be related to enhanced serotonergic activity via reuptake inhibition and agonism and/or antagonism of various serotonin receptors. Vortioxetine may also improve cognitive functioning in MDD, and has proven efficacious in relapse prevention. Nausea was the most commonly reported adverse event (AE); rates of sexual dysfunction were low and abrupt discontinuation was well tolerated. Levomilnacipran ER, a serotonin norepinephrine reuptake inhibitor, demonstrated greater improvement versus placebo in functional impairment as well as depressive symptoms; in post hoc analyses, improvement in symptoms of motivation and energy were observed. Nausea was the most commonly reported AE; gradual discontinuation is recommended to avoid discontinuation syndrome. Vilazodone is a serotonin reuptake inhibitor and partial serotonergic 5-HT1A receptor agonist. In addition to improvement in depressive symptoms, evidence suggests that vilazodone may be particularly well suited for depressed patients with high anxiety levels. Diarrhea, nausea, and headache were the most common AEs; low rates of sexual dysfunction were reported. The 2016 Canadian Network for Mood and Anxiety Treatments guidelines for MDD includes vortioxetine as a first-line treatment; levomilnacipran ER and vilazodone are considered as second-line treatments due to lack of relapse prevention data at the time of approval.

Keywords: serotonin reuptake inhibitor, norepinephrine reuptake inhibitor, depression, major depressive disorder

Plain language summary

Major depressive disorder (MDD) and major depressive episodes are associated with diverse symptoms that cause considerable dysfunction and impairment for patients. Although numerous antidepressants are available in Canada, each patient responds differently to these agents and no single medication has proven itself suitable for everyone. Three new antidepressants – vortioxetine, levomilnacipran extended-release (ER), and vilazodone – have recently become available in Canada. Since each drug has different safety and efficacy characteristics, it is important for clinicians to become familiar with them so they can be used successfully in the clinic.
trials, patients treated with any of the 3 new antidepressants had greater improvement in depressive symptoms than patients treated with placebo; vortioxetine has also demonstrated efficacy in relapse prevention. All 3 antidepressants are generally safe and well tolerated; in clinical trials, nausea was the most common side effect for vortioxetine and levomilnacipran ER, while diarrhea, nausea, and headache were common with vilazodone. The Canadian Network for Mood and Anxiety Treatments guidelines recommend vortioxetine as a first-line treatment for MDD, and levomilnacipran ER and vilazodone are considered as second-line options.

**Introduction**

Major depressive disorder (MDD) and major depressive episode (MDE) are the leading causes of disability in Canada. The majority of patients with MDD experience recurrent or chronic depression (presence of depressive symptoms for ≥2 years), while patients with MDE have an average episode duration of 6 months.¹ The prevalence of MDD or MDE does not appear to be decreasing, despite the availability of psychotherapy and pharmacologic treatments.² Canadian Community Health Study-Mental Health surveys indicate that lifetime and 12-month prevalence rates of MDD and MDE in 2012³ were similar to those in 2002.⁴ Specifically, lifetime MDD prevalence was 10.8% in 2002 and 9.9% in 2012, while 12-month prevalence was 4.0% in 2002 and 3.9% in 2012. Similarly, lifetime MDE prevalence was 12.2% in 2002 and 11.3% in 2012, while 12-month prevalence was 4.8% in 2002 and 4.7% in 2012. Since major depression has been associated with reduced quality of life and decreased life expectancy,⁵ it is a public health concern in Canada.

Although many factors contribute to the continued prevalence of MDD and MDE, the need for better prevention strategies and better quality of treatment is evident.⁶ Many antidepressants are approved for the treatment of MDD in Canada, with generic equivalents available for several branded drugs. The most commonly prescribed antidepressant is the serotonin and norepinephrine reuptake inhibitor (SNRI) venlafaxine, followed by the selective serotonin reuptake inhibitor (SSRI) citalopram (Allergan, data on file, February 2017). Of interest, antidepressants in the SNRI class are prescribed at a higher rate in Canada (30%) than in the USA (~19%) (Allergan, data on file, February 2017). Since symptoms such as energy and concentration difficulties are directly associated with the noradrenergic system,⁷ SNRIs, which increase levels of both serotonin and norepinephrine, may offer advantages for improving depressive symptoms as well as associated functional impairment. However, no single medication has proven itself suitable for all patients, and current prevalence rates for major depression suggest that some sectors of the population are not receiving adequate treatment despite available treatment options.

MDD is heterogeneous in nature comprising disturbances across distinct psychopathological symptoms/domains. Neurochemical (eg, dopaminergic, serotonergic, and noradrenergic) differences in the etiology of symptoms account for some of the heterogeneity in MDD.⁸ However, symptom-based diagnostics greatly contribute to heterogeneity in patient identification since multiple combinations of symptoms from the polythetic list of the *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition* (DSM-5) can qualify a patient for an MDE diagnosis.⁹ It is recognized that the full spectrum of clinical presentations for an MDE is not completely covered by existing symptom criteria, but it may include clinical dimensions (eg, reward abnormalities) with overlapping yet discreet substrates that affect the prognosis and treatment of MDD.⁹ Although episode and course specifiers for an MDE have been retained in the DSM-5,¹ some clinical dimensions (eg, cognitive dysfunction, sleep disturbances, and somatic symptoms) may not be adequately represented. Domain- and dimension-based clinical research approaches in MDD reflect the heterogeneous features of an MDE and attempt to better characterize the domains (eg, fatigue, psychomotor retardation, and lack of motivation) that are relevant to patient-reported outcomes such as quality of life and functional impairment.

Differences in symptoms (eg, fatigue, energy/motivation, and cognitive or functional difficulties), medication type, treatment duration, need for maintenance therapy, and concomitant behavioral therapies are among the factors that influence treatment effectiveness. Currently, many adults with MDD fail to respond adequately to pharmacotherapy and improved therapeutic strategies could benefit patients, providers, and society. In Canada, 3 antidepressant agents have recently become available. This recent and contemporaneous introduction of several new antidepressants provides the impetus to contextualize the differences in their respective mechanistic and clinical profiles. The overarching aim of this review is to provide practitioners with knowledge to support the decision to select any of the new-entry treatments.

**Overview of new antidepressants in Canada**

Between publication of the 2009 and 2016 Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines, vortioxetine, levomilnacipran extended-release (ER), and vilazodone were approved in Canada for the treatment of MDD (Table 1). Vortioxetine has level 1 evidence and is a...
Table 1 New antidepressants in the Canadian market

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Vortioxetine (Trintellix)</th>
<th>Levomilnacipran ER (Fetzima&lt;sup&gt;a&lt;/sup&gt;)</th>
<th>Vilazodone (Viibryd&lt;sup&gt;b&lt;/sup&gt;)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indication</td>
<td>Major depressive disorder</td>
<td>Major depressive disorder</td>
<td>Major depressive disorder</td>
</tr>
<tr>
<td>Mechanism of action&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Selective serotonin reuptake inhibitor, 5-HT&lt;sub&gt;1A&lt;/sub&gt; antagonist, 5-HT&lt;sub&gt;1B&lt;/sub&gt; agonist</td>
<td>Serotonin and norepinephrine reuptake inhibitor</td>
<td>Selective serotonin reuptake inhibitor and 5-HT&lt;sub&gt;1A&lt;/sub&gt; partial agonist</td>
</tr>
<tr>
<td>Dosing recommendation</td>
<td>Once-daily with or without food; initiate at 10 mg/day and increase to 20 mg/day as tolerated; dose can be reduced to 5 mg/day in patients who do not tolerate higher doses</td>
<td>Once-daily with or without food; initiate at 20 mg/day for 2 days and increase to 40 mg/day; increase by 40 mg increments to 120 mg/day at 2-day intervals, as needed and tolerated</td>
<td>Once-daily with food; initiate at 10 mg/day for 7 days; increase to 20 mg/day then 40 mg/day at 7-day intervals, as needed and tolerated</td>
</tr>
<tr>
<td>Primary efficacy measures in clinical trials</td>
<td>MADRS or HAM-D</td>
<td>MADRS</td>
<td>MADRS</td>
</tr>
<tr>
<td>Additional measures of interest</td>
<td>SDS, DSST</td>
<td>SDS, MEI</td>
<td>HAM-A, CSFQ, ASEX</td>
</tr>
<tr>
<td>Common adverse reactions (drug/placebo, %)&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Nausea (26/9), diarrhea (8/6), dry mouth (7/6), dizziness (7/6), constipation (5/3), vomiting (5/1)</td>
<td>Nausea (17/6), constipation (9/3), hyperhidrosis (9/2), tachycardia (6/2), erectile dysfunction (6/1 [men only]), heart rate increased (6/1), vomiting (5/1), palpitations (5/1), ejaculation disorder (5/1 [men only])</td>
<td>Diarrhea (28/10), nausea (24/7), headache (14/14), dry mouth (7/5), insomnia (6/2), vomiting (5/2), somnolence (5/2), abdominal pain (5/3)</td>
</tr>
</tbody>
</table>

Notes: <sup>a</sup>Proposed mechanism of action based on current knowledge; mechanisms are not fully understood for any of these 3 medications. <sup>b</sup>Reported in ≤5% of actively treated patients in any dose group (vortioxetine, vilazodone) or all dose groups combined (levomilnacipran ER), as analyzed and described in the relevant US prescribing information; percent values presented in the table are based on all dose groups combined. 

Abbreviations: ASEX, Arizona Sexual Experiences Scale; CSFQ, Changes in Sexual Functioning Questionnaire; DSST, digit symbol substitution test; eR, extended-release; HAM-A, Hamilton Rating Scale for Anxiety; HAM-D, Hamilton Rating Scale for Depression; MADRS, Montgomery–Åsberg Depression Rating Scale; MEI, Motivation and Energy Inventory; SDS, Sheehan Disability Scale.

First-line treatment for MDD; although levomilnacipran ER and vilazodone also have level 1 evidence, lack of clinical experience in prescribing them and limited long-term efficacy data currently relegate them to second-line treatments.<sup>e</sup> 

Vortioxetine 

Mechanisms underlying the antidepressant effects of vortioxetine are not fully understood, but enhancement of serotonergic activity via reuptake inhibition is believed to be a contributing factor; other potential mechanisms include agonism and/or antagonism of various serotonin receptors (eg, 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>3</sub>, 5-HT<sub>1D</sub>, and 5-HT<sub>2C</sub>).<sup>11,12</sup> Vortioxetine is taken once daily with or without food;<sup>11</sup> the recommended starting dose is 10 mg/day, which can be increased to 20 mg/day as needed and tolerated. Lowering the dose to 5 mg/day may be considered in patients with tolerability issues. Importantly, vortioxetine is associated with a low level of discontinuation symptoms, which may be partly related to its relatively long elimination half-life, and abrupt discontinuation is well tolerated.<sup>13,14</sup>

In Canada, approval of vortioxetine for the acute treatment of MDD was based on a review of 11 short-term (6 or 8 weeks) Phase III studies, which included 6 positive studies of vortioxetine 5–20 mg/day in adults,<sup>15–17</sup> vortioxetine 20 mg/day in adults,<sup>18,19</sup> and vortioxetine 5 mg/day in older adults (≥65 years).<sup>20</sup> In non-US trials, efficacy was shown across a wide dose range, with lower doses (5, 10, and 15 mg/day) and the highest dose (20 mg/day) reaching statistical significance versus placebo. In US trials, only the 20 mg/day dose was significantly different than placebo, which led the US Food and Drug Administration to recommend a starting dose of 10 mg/day, with an increase to 20 mg/day as tolerated.<sup>11</sup>

In a meta-analysis of vortioxetine studies, significantly greater decreases in Montgomery–Asberg Depression Rating Scale (MADRS) total score were shown for vortioxetine (5, 10, and 20 mg/day) versus placebo.<sup>21</sup> Treatment effects appeared to be dose-related, which is consistent with the dose-related pharmacokinetics of vortioxetine.<sup>11</sup> Placebo-controlled studies also suggest that treatment with vortioxetine can improve cognitive functioning in patients with MDD, independent of the drug’s effects on symptoms of depression.<sup>22–24</sup> It is hypothesized that the procognitive effects of vortioxetine involve a combination of monoaminergic and glutamatergic effects.<sup>23</sup> Vortioxetine has also been shown to prevent MDD relapse and is well tolerated as maintenance therapy.<sup>25</sup> Nausea was the only adverse event (AE) reported in >10% of all vortioxetine-treated patients during placebo-controlled trials (Table 1).<sup>11</sup> Given that sexual dysfunction is
a known side effect of antidepressant treatment, it is noteworthy that vortioxetine has demonstrated placebo-level sexual dysfunction at initiation doses of 10 mg/day.\textsuperscript{13} Although rates of sexual dysfunction are higher at doses of 15–20 mg/day compared with 10 mg/day (albeit lower than SSRI treatment), switching to vortioxetine has been shown to be beneficial for patients experiencing sexual dysfunction during antidepressant therapy with SSRIs.\textsuperscript{37} Sexual dysfunction was reported in <2% of placebo- and vortioxetine-treated patients in placebo-controlled trials.\textsuperscript{13}

**Levomilnacipran ER**

Levomilnacipran ER, the more active enantiomer of the racemic drug milnacipran, is an SNRI with preferential inhibition of norepinephrine reuptake in vitro.\textsuperscript{28,29} Levomilnacipran exhibits higher affinity for norepinephrine and serotonin transporters and more potently inhibits norepinephrine and serotonin reuptake than milnacipran.\textsuperscript{29}
The recommended dose is 40–120 mg once daily, with or without food; levomilnacipran ER is initiated at 20 mg/day for 2 days and then increased to 40 mg/day. Based on tolerability and efficacy, the dose can be increased in 40 mg/day increments every 2 or more days until the highest recommended dose (120 mg/day) is reached.\textsuperscript{28} Since symptoms (eg, nausea, sweating, dysphoric mood, irritability, agitation, and dizziness) have been reported when serotonergic drugs are discontinued, gradual dose reduction, instead of abrupt discontinuation, is recommended for levomilnacipran ER whenever possible. Patients should be monitored and a more gradual dose reduction can be considered if symptoms are intolerable.\textsuperscript{28}

Four short-term (8 or 10 weeks) placebo-controlled trials of levomilnacipran ER were included in the Health Canada review, including 3 positive studies (2 fixed dose\textsuperscript{30,31} and 1 flexible dose\textsuperscript{32}). In these studies, changes from baseline in MADRS total score (primary endpoint) and Sheehan Disability Scale (SDS; secondary endpoint) were significantly different in favor of levomilnacipran ER versus placebo, indicating greater improvement in depressive symptoms and functional impairment. Among the SDS subscales, significant improvement was also found on the work subscale in all 3 studies, and on the social life and family life subscales in 2 studies. At the time of the Health Canada review, a levomilnacipran ER relapse prevention study had not been completed (NCT02288325); however, subsequently reported results showed that continued treatment in patients who had responded to levomilnacipran ER (40–120 mg/day) significantly reduced the risk of relapse relative to placebo over 26 weeks of double-blind treatment.\textsuperscript{33}

Post hoc analyses of clinical study data have indicated that levomilnacipran ER can improve motivation and energy,\textsuperscript{34} which is consistent with its noradrenergic effects.\textsuperscript{35} Larger treatment effects on functional impairment and mental functional health were observed in patients with low versus high baseline motivation and energy.\textsuperscript{34} In addition, a meta-analysis of 5 randomized placebo-controlled studies showed that levomilnacipran ER improved depression across a range of symptoms and symptom domains, including anhedonia and retardation.\textsuperscript{36}

In placebo-controlled trials, nausea was the only AE reported in >10% of all levomilnacipran ER-treated patients (Table 1).\textsuperscript{28} No unexpected or inconsistent safety issues were found during a 48-week open-label extension study in which patients received levomilnacipran ER (40, 80, or 120 mg/day)\textsuperscript{37} or during the relapse prevention trial.\textsuperscript{33}

**Vilazodone**

Vilazodone is a serotonin reuptake inhibitor and partial serotonergic 5-HT\textsubscript{1A} receptor agonist.\textsuperscript{38} The recommended target dose is 20–40 mg/day taken once daily with food. The initial 10-mg/day dose is taken for 7 days, followed by increases to 20 mg/day then to 40 mg/day, with intervals of 7 days or more in between; this slower dose titration is recommended to avoid acute gastrointestinal side effects that may develop initially.\textsuperscript{38,39} Additionally, to avoid adverse reactions associated with serotonin discontinuation syndrome, gradual dosage reduction, rather than abrupt cessation, is recommended when treatment with vilazodone is discontinued.\textsuperscript{38}

In the 4 short-term (8 or 10 weeks) Phase III trials that were reviewed for Canadian approval, significantly greater improvements in depression symptoms were seen with vilazodone (20–40 mg/day) versus placebo.\textsuperscript{40–43} In a post hoc pooled analysis of data from 2 clinical trials, statistically significant differences in favor of vilazodone versus placebo were seen in changes from baseline on rating scales measuring depression, global illness severity, and anxiety; significant improvement was also seen for vilazodone versus placebo on each individual item of the MADRS, suggesting efficacy across a spectrum of depressive symptoms.\textsuperscript{44} Additional post hoc analyses of MDD clinical trial data,\textsuperscript{44} along with results from clinical studies in patients with generalized anxiety disorder,\textsuperscript{36–41} suggest that vilazodone may be particularly well suited for patients suffering from depression and having high levels of anxiety.

In placebo-controlled trials, AEs reported in >10% of all vilazodone-treated patients included diarrhea, nausea, and headache (Table 1).\textsuperscript{38} No unexpected safety concerns were found in a 12-month open-label study of vilazodone
40 mg/day in patients with MDD.\(^4\) Weight gain in the long-term MDD study was small (mean increase +1.7 kg),\(^5\) in contrast to mean weight gains seen in long-term studies of other SSRI drugs (up to ~10 kg).\(^6\) Additionally, vilazodone had no significant placebo-subtracted effect on sexual functioning in patients with MDD\(^7\) or in healthy adult volunteers,\(^8\) which is an important factor to consider when treating patients with sexual dysfunction associated with antidepressant treatment or with depressive disorder itself.

### Treatment considerations, algorithms, and evidence-based guidelines

Although existing treatment guidelines and algorithms for depression may differ in terms of specific steps, they generally encourage an individualized approach that considers specific factors that may contribute to the treatment outcome (eg, concomitant medications, tolerability, and prominent symptoms). Concomitant medications and potential drug interactions should be considered when selecting treatments. Based on in vitro studies, levomilnacipran ER is predicted to have low potential for pharmacokinetic drug interactions.\(^9\) Vortioxetine dose should be reduced by half when co-administered with a strong CYP2D6 inhibitor (eg, bupropion, fluoxetine, paroxetine, and quinidine), and the dose may need to be increased when co-administered with a strong CYP inducer (eg, rifampin, carbamazepine, and phenytoin).\(^10\) Vilazodone dose should not exceed 20 mg/day when co-administered with strong CYP3A4 inhibitors, and the dose may need to be increased when co-administered with CYP3A4 inducers.\(^11\) Additionally, for all the 3 drugs, co-administration with other serotonergic drugs should be closely monitored due to increased risk of serotonin syndrome.

The 2016 CANMAT algorithm\(^12\) includes vortioxetine, several SNRIs (eg, venlafaxine), and several SSRIs as first-line treatments based on a systematic literature review of antidepressants that evaluated quality of evidence and clinical expert consensus; agomelatine, bupropion, and mirtazapine are additional first-line recommendations. Levomilnacipran ER and vilazodone are included as second-line treatments due, in part, to the lack of relapse prevention data; however, as noted previously, top-line results from a recently completed study indicate that levomilnacipran ER has significant effects on relapse prevention relative to placebo.\(^13\) The Florida Best Practice Psychotherapeutic Medication Guidelines for Adults (2015) begins with a recommendation to assess the history of hypomania/mania, psychiatric and medical comorbidities, DSM-5 specifiers (eg, psychosis, mixed features, and suicidality), and the presence of cognitive dysfunction.\(^14\) For initial treatment of MDD with no specifiers or MDD with mixed features, this guideline includes SSRIs (eg, vilazodone), SNRIs (eg, levomilnacipran ER), and vortioxetine (in patients with cognitive complaints). For MDD with psychosis, the first-line recommendation is an SSRI or SNRI in conjunction with a second-generation antipsychotic medication; the guideline does caution, however, that risks for extrapyramidal symptoms, weight gain, and metabolic concerns should be considered before initiating adjunctive antipsychotic treatment.

### Conclusion

Many clinical features and medication characteristics influence the choice of antidepressant treatment. Since the relative differences in efficacy between available medications are small, selecting an antidepressant should involve assessing individualized patient needs, symptoms, and preferences.

### Acknowledgments

Writing and editorial assistance was provided by Mildred Bahn, MA, at Prescott Medical Communications Group (Chicago, IL, USA), with support from Allergan (Jersey City, NJ, USA) in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

### Author contribution

Dr. McIntyre provided the initial outline and maintained full control over the direction and development of the manuscript. The author contributed toward data analysis, drafting, and revising the paper and agrees to be accountable for all aspects of the work.

### Disclosure

Dr. McIntyre has received research grant support from Lundbeck, AstraZeneca, Pfizer, Shire, Otsuka, Bristol-Myers Squibb, National Institute of Mental Health, Stanley Medical Research Institute, Canadian Institutes for Health Research, and The Brain and Behavior Research Foundation. He has also received speaker/consultant fees from Lundbeck, Pfizer, AstraZeneca, Eli Lilly, Janssen Ortho, Sunovion, Takeda, Forest, Otsuka, Bristol-Myers Squibb, and Shire. The author reports no other conflicts of interest in this work.

### References


